Librela is generally well tolerated by most dogs, but it carries real risks that every owner should understand before starting treatment. The drug was approved to control osteoarthritis pain in dogs, and it works differently from traditional pain relievers. However, the FDA issued a letter to veterinarians in late 2024 after evaluating reports of serious adverse events, including neurological problems and, in some cases, death. Here’s what the evidence actually shows.
How Librela Works
Librela contains bedinvetmab, a monoclonal antibody designed specifically for dogs. Instead of reducing inflammation the way NSAIDs do, it targets a protein called nerve growth factor (NGF) that plays a key role in chronic pain signaling. By binding to NGF and blocking it from reaching pain receptors, the drug interrupts pain at its source without passing through the liver or kidneys the way traditional painkillers do.
This mechanism is one reason veterinarians initially considered it a safer alternative for dogs with kidney disease, liver problems, or gastrointestinal sensitivity, since NSAIDs can damage those organs over time. In laboratory safety studies, bedinvetmab at doses up to 10 times the normal amount was well tolerated in healthy Beagles over six months, with no adverse changes in organ function, neurological exams, eye exams, joint health, or immune function. It was also tested alongside the NSAID carprofen for two weeks with no additional safety concerns.
Common Side Effects
In the main U.S. field study used for FDA approval, 135 dogs received Librela and 137 received a saline placebo over 84 days. The most frequently reported reactions were mild and localized:
- Skin redness at the injection site: 4.4% of treated dogs, compared to 3.6% in the placebo group
- Pain on injection: 3.0% of treated dogs, compared to 1.5% in the placebo group
One dog with a history of skin allergies developed mild hair loss and redness at the injection site after two separate doses. Both episodes resolved with treatment. For most dogs, the injection itself is the only noticeable event, and side effects at the site tend to be brief.
The FDA’s 2024 Safety Alert
In December 2024, the FDA’s Center for Veterinary Medicine published a “Dear Veterinarian” letter after completing an evaluation of adverse event reports submitted since Librela reached the market. The agency identified several categories of concern:
- Ataxia: loss of coordination or unsteady movement
- Seizures
- Other neurological signs: including partial paralysis, inability to stand, and urinary incontinence
- Excessive thirst and urination
In some of these reported cases, the outcome was death or euthanasia. The FDA noted that it does not currently have the authority to mandate labeling changes for animal drugs, but it continues to monitor the drug’s safety profile and can request that the manufacturer update labels, conduct post-approval studies, or increase reporting frequency.
It’s important to understand what adverse event reports do and don’t tell us. These are voluntary reports from veterinarians and owners, and they don’t establish that the drug caused the problem. Dogs being treated for osteoarthritis are often older and may have other conditions that could explain neurological decline. Still, the pattern was significant enough for the FDA to take the unusual step of issuing a public letter.
Which Dogs Should Not Receive Librela
The label lists clear restrictions. Librela should not be used in pregnant, lactating, or breeding dogs. Its safety and effectiveness have not been evaluated in dogs younger than 12 months. Because the drug blocks nerve growth factor, there is a theoretical concern about interfering with nervous system development in young or growing animals, though formal studies in puppies have not been published.
There are no specific label contraindications for dogs with kidney or liver disease, which is part of the drug’s appeal. But the post-market neurological reports mean that dogs with any pre-existing neurological condition warrant extra caution. If your dog has a history of seizures, disc disease, or mobility problems unrelated to arthritis, discuss these with your veterinarian before starting treatment.
What to Watch for After an Injection
Librela is given as a once-monthly injection at your veterinarian’s office, dosed by body weight. Because it’s a monoclonal antibody rather than a conventional drug, it can’t be “undone” once injected. If your dog has an adverse reaction, the antibody will remain active in the body for weeks until it naturally breaks down. This is worth considering: with a daily pill, you can simply stop giving it, but a monthly injection commits your dog to that dose for roughly 30 days.
In the first few days after each injection, watch for wobbliness, dragging of the hind legs, difficulty standing, changes in urination patterns, or any behavior that suggests confusion or disorientation. Mild soreness or redness at the injection site is normal and typically resolves on its own. If you notice anything neurological, contact your veterinarian promptly. Many dogs that respond poorly to one dose are not given additional injections, and symptoms in some reported cases resolved after the drug cleared the system.
How It Compares to Other Pain Options
For dogs with osteoarthritis, the main alternatives are NSAIDs, which are effective but carry risks of gastrointestinal bleeding, kidney damage, and liver toxicity, especially with long-term use. Librela avoids those specific organ risks because of its targeted mechanism. In the original safety studies, there were no treatment-related changes in organ function even at triple and ten-times the standard dose over six months.
The tradeoff is a different risk profile. NSAIDs have decades of use behind them, and their side effects are well characterized and generally predictable through routine bloodwork. Librela is newer, and the neurological risks flagged by the FDA are still being defined. For a dog with compromised kidneys that can’t tolerate anti-inflammatory drugs, Librela may be the better option despite these concerns. For a dog with no organ issues, the calculus is less clear-cut, and the decision often comes down to how your dog responds individually.
Many dogs do well on Librela for months or years with noticeable improvements in mobility and quality of life. The adverse events, while serious, appear to affect a small percentage of treated animals. Keeping a record of your dog’s behavior, energy level, and coordination before and after each injection gives you and your veterinarian the best basis for deciding whether to continue.